1[1]Reist M,Carrupt PA,Francotte E,et al.Chiral inversion and hydrolysis of thalidomide:mechanisms and catalysis by bases and serum albumin,and chiral stability of teratogenic metabolites.Chem Res Toxicol,1998,11(12):1512～1528
2[2]Teo SK,Sabourin PJ,O'Brein K,et al.Metabolism of thalidomide in human microsomes,cloned human cytochrome P-450 isozymes,and Hansen's disease patients.Biochem Mol Toxicol,2000,14(3):140～147
3[3]Quilita R.Thalidomide in oncology:the peril and the promise.Cancer Control,1999,6(5):483～495
4[4]D'Amato RJ,Loughnan MS,Flynn E,et al.Thalidomide is an inhibitor of angiogenesis.Proc Natl Acad Sci USA,1994,91:4082～4085
5[5]Peuckmann V,Fisch M,Bruera E,et al.Potential novel uses of thalidomide:focus on palliative care.Drugs,2000,60(2):273～292
6[6]Argiles JM,Carbo N,Lopez SFJ,et al.Was tumour necrosis factor-alpha responsible for the fetal malformations.Med Hypotheses,1998,50(4):313～318
7[7]Coleman M,Leonard JP,Nahum K,et al.Non-myelosuppre-ssive therapy with blt-d (Bianxin(r),low dose thalidomide and dexamethasone) is highly active in Waldenstrom's macroglobulinemia and myeloma.Blood,2000,96(11):167a
8[8]Haslett PA,Corral LG,Albert M,et al.Thalidomide costimulates primary human T lymphocytes,preferentially inducing.J Exp Med,1998,187(11):1885～1892
9[9]Hideshima T,Chauhan D,Shima Y,et al.Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.Blood,2000,96(9):2943～2950
10[10]Geitz H,Handt S,Zwingenberger K,et al.Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade.Immunopharmacology,1996,31(2-3):213～221
4Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in ad- vanced and refractory multiple myeloma after single-agent thalido- mide :identification of prognostic factors in a phasse 2 study of 169 patients[J,]. Blood,2001,98(2) :492-494.
5Davies FE, Raje N, Hideshima T, et al. Thalidomide and immu- nomodu-latory derivatives augment natural killer cell cytotoxicity in multiple myeloma[J]. Blood,2001,98(1) :210-216.
6Osman K, Comenzo R, Rajkumar SV. Deep venous thrombosis and thalidomide therapy for multiple myeloma[J]. N EngI J Med, 2001, 344:1951.
7Hatsue Ogawara,Hiroshi Handa,Tohru Yamazaki,Takuma Toda,Kensuke Yoshida,Natsumi Nishimoto,Wedad Hamdi Saleh Al-ma’Quol,Yoriaki Kaneko,Takafumi Matsushima,Norifumi Tsukamoto,Yoshihisa Nojima,Morio Matsumoto,Morio Sawamura,Hirokazu Murakami.High Th1/Th2 ratio in patients with multiple myeloma[J]. Leukemia Research . 2004 (2)
8Zhao Yu,Dou Li-ping,Wang Shu-hong,Bo Jian,Wang Quan-shun,Huang Wen-rong,Jing Yu,Gao Chun-ji,Li Hong-hua,Zhu Hai-yan,Han Xiao-ping,Yu Li.[The efficacy and safety of PAD and VAD regimens for untreated multiple myeloma]. Zhonghua nei ke za zhi [Chinese journal of internal medicine] . 2010
9Mu Hao,Li Zhang,Gang An,Weiwei Sui,Zhen Yu,Dehui Zou,Yan Xu,Hong Chang,Lugui Qiu.Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells. Journal of Hematology & Oncology . 2011
10Palumbo A,Anderson K.Multiple myeloma. The New England Journal of Medicine . 2011
